Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We reported another quarter of digit growth in our growth portfolio and progressed our plans to de-risk the pipeline to position the company for long-term success. We have seen several positive registrational readouts and regulatory approvals over the past few months, and we expect more to come, bringing the next wave of launches into sharper focus. ? We are executing well commercially, ? our differentiated pipeline is advancing nicely, and we continue to operate with discipline, which gives us strategic flexibility to invest for sustainable growth. Based on the strength of our results, we are raising our full year guidance. David will provide additional details on this shortly. Let me start with our Q3 performance on slide four. ? Our growth portfolio continues to deliver solid results with sales increasing 12%, driven by a broad set of differentiated products. We generated strong performance in key brands including Reblazil, Brianzi, OptuLag, Cuvantic, and Camzios. We also continue to expand the reach of our medicines. In September, Camzios received approval for an expanded indication and became the only FDA approved therapy for pediatric patients with obstructive HCM. We also achieved an important milestone in the quarter with the FDA's accelerated approval of Zimbexis, the first approved cell mod, and the newest addition to our portfolio. Zimbexis is approved for the treatment of multiple myeloma, where the combination of a highly efficacious and convenient oral option is an important treatment advancement for patients in both community and academic settings. We are encouraged by positive early launch feedback and by the compelling phase three data we announced earlier this month, where Zimbexis demonstrated a meaningful improvement in progression free survival. We will present these data at ASH in December. These results further strengthen our conviction in cell mods ? and our broader targeted protein degradation platform, where BMS is a clear leader. Behind Zimbexis, our second cell mod, Mazigdomide, has a PADUFA date of May 13, 2027. Mazygdomide offers the potential to introduce another highly efficacious and convenient oral option for a different segment of multiple myeloma patients. We also continue to advance glaucotamide in lymphoma and will present the first phase two data in frontline follicular lymphoma at ASH. The momentum in our late stage pipeline has accelerated. In the past two months alone, we announced positive data for four registrational studies. These include Zymbexis PFS, as I mentioned earlier, admilparent in idiopathic pulmonary fibrosis, interim results for rays 101 in GEP nets, and R low cell in relapsed and refractory multiple myeloma. Let me comment on the last three. Admirant, met its primary endpoint at the 60 milligram dose with a favorable safety and tolerability profile that supports its potential as a first in class IPF treatment. IPF is a progressive and often fatal disease where there remains a need for effective, well tolerated treatment options like admilparint. We will discuss the IPF results with regulators and expect phase three results in progressive pulmonary fibrosis in the first quarter of next year. PPF is a larger opportunity in another area where admilparin has significant commercial potential. With respect to RAISE 101, our tinium-based radiopharmaceutical therapy, we're encouraged by the interim readouts in GEPNATs. These results demonstrated a clinically meaningful improvement in PFS in patients whose disease has progressed following existing lutetium-based therapy. These were the first phase three results for an alpha-emitting targeted RPT, representing an important milestone for RAIS 101 and further strengthening our conviction in radiopharmaceuticals as a platform. We are engaging with the FDA on next steps towards regulatory submission. Finally, RLOSAL, our GPRC 5D direct at CART, delivered positive results ? in the registrational phase two quintessential study this September, a milestone that underscores its potential to set a new standard of care in the post-BCMA multiple myeloma market. This study represents the only prospective trial exclusively conducted in the post-BCMA quadruple class exposed setting, a growing patient population with poor outcomes and no therapies approved specifically for this segment. As these programs advance, we are building the Manufacturing Foundation for the next generation of our medicines with two U.S. investments recently announced. In Houston, we shared plans for a new state of the art manufacturing campus at Generation Park, an approximately $2.3 billion investment that will create nearly 500 skilled jobs. This facility ? will give us manufacturing flexibility across small molecules, biologics, and antibody drug conjugates. It is also designed to evolve and scale to meet patient needs for decades to ? come. In Indiana, RAISE Bio is investing more than $170 million to establish a new radio pharmaceutical manufacturing facility, complementing its existing footprint in the state and creating up to 100 new jobs by the end of 2029. Together, these investments support the next wave of medicines coming through our pipeline and advance our U.S. manufacturing commitments. Turning to slide five, as we look ahead, we have several meaningful readouts over the remainder of 2026 and into 2027. Before year end, we expect phase three data for MOLVEXIAN and secondary stroke prevention and SOTIC 2 and LUPIS. ? With COBINFI, we will share open label Alzheimer's disease psychosis data from the ADEP 1 and from the Long-Term Extension ADEP 3 studies at CTAD next month. In 2027, we continue to expect results for MILVECIN and atrial fibrillation in the first quarter. We also anticipate additional data from the broader ADEP program, bipolar one data from the COBINFI balsam studies, and the first registrational registrational data for golcotamide in high-risk first line LBCL. ? So while we have made good progress in our pipeline, there's more to ? come. As we close out the year and move into 2027, we are focused on a few key priorities as noted on slide six. First, sustaining the momentum across our growth portfolio. We now have eight growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers. Second, translating pipeline progress into filings, approvals, and successful launches. Zinbexis is an early example of that progression, and as additional studies read out, our focus will be on launch preparedness and moving with urgency to bring these medicines to patients. Third, continuing to rewire how we operate. We're focused on becoming faster and more efficient in RD, and over the past year, we have made changes across the organization to strengthen how we design and conduct clinical trials. At the same time, we continue to drive productivity and efficiency, including through our organizational structure, capital allocation decision making process, and the use of technology. That discipline gives us flexibility to invest behind the growth portfolio and pipeline, pursue business development where it makes sense, and return cash to shareholders. Taken together, we are entering the final quarter of the year with real momentum. Our growth portfolio is performing well. We're advancing our pipeline with meaningful wins, ? and remain highly disciplined in ensuring our cost structure is aligned with our revenue base. The team is energized and focused on delivering value for patients and our shareholders. With that, I'll turn it over to David.
Passages & reports (42) 2:22 Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We rep… Report 2:42 months, and we expect more to come, bringing the next wave of launches into sharper focus. Report 2:48 We Report 2:49 are executing well commercially, Report 2:51 our Report 2:51 differentiated pipeline is advancing nicely, and we continue to operate with discipline, w… Report 3:11 four. Report 3:11 Our Report 3:12 growth portfolio continues to deliver solid results with sales increasing 12%, driven by a… Report 3:32 received approval for an expanded indication and became the only FDA approved therapy for … Report 3:52 treatment of multiple myeloma, where the combination of a highly efficacious and convenien… Report 4:11 progression free survival. We will present these data at ASH in December. These results fu… Report 4:19 and Report 4:19 our broader targeted protein degradation platform, where BMS is a clear leader. Behind Zim… Report 4:39 myeloma patients. We also continue to advance glaucotamide in lymphoma and will present th… Report 4:59 PFS, as I mentioned earlier, admilparent in idiopathic pulmonary fibrosis, interim results… Report 5:19 profile that supports its potential as a first in class IPF treatment. IPF is a progressiv… Report 5:39 next year. PPF is a larger opportunity in another area where admilparin has significant co… Report 5:59 in patients whose disease has progressed following existing lutetium-based therapy. These … Report 6:19 steps towards regulatory submission. Finally, RLOSAL, our GPRC 5D direct at CART, delivere… Report 6:27 in Report 6:27 the registrational phase two quintessential study this September, a milestone that undersc… Report 6:47 poor outcomes and no therapies approved specifically for this segment. As these programs a… Report 7:07 $2.3 billion investment that will create nearly 500 skilled jobs. This facility Report 7:13 will Report 7:14 give us manufacturing flexibility across small molecules, biologics, and antibody drug con… Report 7:24 come. Report 7:25 In Indiana, RAISE Bio is investing more than $170 million to establish a new radio pharmac… Report 7:45 pipeline and advance our U.S. manufacturing commitments. Turning to slide five, as we look… Report 8:04 With Report 8:04 COBINFI, we will share open label Alzheimer's disease psychosis data from the ADEP 1 and f… Report 8:24 program, bipolar one data from the COBINFI balsam studies, and the first registrational re… Report 8:35 So Report 8:35 while we have made good progress in our pipeline, there's more to Report 8:38 come. As Report 8:39 we close out the year and move into 2027, we are focused on a few key priorities as noted … Report 8:59 Second, translating pipeline progress into filings, approvals, and successful launches. Zi… Report 9:18 focused on becoming faster and more efficient in RD, and over the past year, we have made … Report 9:38 technology. That discipline gives us flexibility to invest behind the growth portfolio and… Report 9:57 meaningful wins, Report 9:58 and Report 9:59 remain highly disciplined in ensuring our cost structure is aligned with our revenue base.… Report